Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients.

Sakata, Y; Ohtsu, A; Horikoshi, N; Sugimachi, K; Mitachi, Y; Taguchi, T

Sakata, Y; Ohtsu, A; Horikoshi, N; Sugimachi, K; Mitachi, Y; Taguchi, T.

Affiliation

Sakata Y; Department of Gastroenterology, Aomori Prefectural Central Hospital, Japan.

Eur J Cancer ; 34(11): 1715-20, 1998 Oct.

Article in En | MEDLINE | ID: mdl-9893658

Subject(s)

Antimetabolites, Antineoplastic/administration & dosage; Oxonic Acid/administration & dosage; Pyridines/administration & dosage; Stomach Neoplasms/drug therapy; Tegafur/administration & dosage; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic/adverse effects; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid/adverse effects; Pyridines/adverse effects; Stomach Neoplasms/pathology; Survival Analysis; Tegafur/adverse effects; Treatment Outcome

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Oxonic Acid / Pyridines / Stomach Neoplasms / Tegafur / Antimetabolites, Antineoplastic Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Eur J Cancer Year: 1998 Type: Article Affiliation country: Japan

Search on Google

XML

PubMed Links